期刊文献+

糖皮质激素治疗先天性纯红细胞再生障碍性贫血的远期并发症 被引量:2

Investigation on long - term complications of glucocorticoid in treatment of Diamond - Blackfan anemia
原文传递
导出
摘要 目的总结糖皮质激素(GC)治疗先天性纯红细胞再生障碍性贫血(DBA)的远期并发症。方法收集2009年12月至2012年11月首都医科大学附属北京儿童医院诊治的应用GC治疗〉1年的17例DBA患儿资料,记录患儿一般情况、开始治疗时间、用药情况、治疗反应、不同时期身高和体质量、治疗相关不良反应等数据,采用SPSS16.0软件进行数据录入及统计学分析。结果符合纳入标准并具有详细长期随访资料的DBA共17例。58.8%(10/17例)的患儿开始GC治疗时年龄〈6个月。76.4%(13/17例)的患儿初始泼尼松用量≥2mg/(kg·d),此剂量维持治疗中位时间为2个月(1~5个月)。泼尼松用量〉0.5mg/(kg·d)的中位时间为6个月(3~48个月)。以用药时年龄是否≥6个月,将患儿分为小年龄组及大年龄组。开始治疗时,小年龄组中位身高为同年龄同性别标准身高的-1.0标准差(SD)(-3.5~1.0SD),用药0.5年后降为-3.5SD(-3.5SD~-2.0SD);而大年龄组则分别为0.0SD(-1.5~2.0SD)和-0.5SD(-1.5~0.5SD)。治疗过程中,出现1例骨折,2例麻疹肺炎,3例反复肺炎,3例多毛,5例鹅口疮,12例向心性肥胖。结论DBA患儿长期应用GC治疗,可出现激素相关不良反应。建议临床医师尽量于患儿6个月后开始GC治疗,尽量缩短〉0.5mg/(kg·d)泼尼松口服维持时间。 Objective To collect and summarize long - term complications of glueocortieoid (GC) in treat- ment of Diamond - Blaekfan anemia ( DBA). Methods A total of 17 DBA patients,treated with GC more than 1 year from December 2009 to November 2012 in Being Children's Hospital, Capital Medical University,were retrospectively investigated. The data of general information, drug treatment, treatment response, height and body mass in different the- rapy periods, and therapy related adverse reaction were collected. The data entry and the statistical analysis were per- formed using SPSS 16.0 software. Results Seventeen cases which fulfilled the research criteria were enrolled. The 58.8 percent of cases (10/17) began GC therapy from the age younger than 6 months. The 76.4 percent of the cases (14/17) started prednisone therapy with the dosage≥2 mg/( kg · d),and the median time of maintenance therapy with this dosage was 2 months ( 1 -5 months). The median time of prednisone dosage greater than 0.5 mg/( kg · d) was 6 months (3 -48 months). Patients were divided into 2 groups at the beginning of therapy according to whether their age was younger or older than 6 mouths. The median height of younger age group was - 1.0 SD ( - 3.5 - 1.0 SD) of corresponded age - sex - standard height at the beginning of prednisone therapy, and was dropped to - 3.5 SD ( -3.5 - -2.0 SD)after half year treatment. For older age group, it was 0.0 SD ( - 1.5 -2.0 SD)and -O. 5 SD ( - 1.5 - 0. 5 SD) respectively. During the therapy, there were 1 fracture,2 measles pneumonia, 3 pneumonia, 3 hi- rsuitisms ,5 thrushes, and 12 central obesity cases. Conclusions GC related adverse reaction might appear when app- lying prednisone for the treatment of DBA in long term. It was suggested that GC therapy should start after 6 months old if possible,and the duration of 0.5 mg/( kg · d) GC treatment should be reduced as short as possible.
出处 《中华实用儿科临床杂志》 CAS CSCD 北大核心 2015年第15期1184-1187,共4页 Chinese Journal of Applied Clinical Pediatrics
基金 教育部高等学校博士学科点专项科研基金(20101107120012) 北京市医院管理局J临床医学发展专项经费(ZY201404)
关键词 先天性纯红细胞再生障碍性贫血 糖皮质激素 并发症 生长发育 Diamond - Blaekfan anemia Glucocortieoid Complication Growth status
  • 相关文献

参考文献15

  • 1KhinchaPP, SavageSA.Genomic characterization of the inherited bone marrow failure syndromes[J].Semin Hematol, 2013, 50(4):333-347.
  • 2RuggeroD, ShimamuraA.Marrow failure:a window into ribosome biology[J].Blood, 2014, 124(18):2784-2792.
  • 3SakaguchiH, NakanishiK, KojimaS.Inherited bone marrow failure syndromes in 2012[J].Int J Hematol, 2013, 97(1):20-29.
  • 4KimSK, AhnHS, BackHJ, et al.Clinical and hematologic manifestations in patients with Diamond Blackfan anemia in Korea[J].Korean J Hematol, 2012, 47(2):131-135.
  • 5PosPisilovaD, CmejlovaJ, LudikovaB, et al.The Czech National Diamond-Blackfan Anemia Registry:clinical data and ribosomal protein mutations update[J].Blood Cells Mol Dis, 2012, 48(4):209-218.
  • 6ChungNG, KimM.Current insights into inherited bone marrow failure syndromes[J].Korean J Pediatr, 2014, 57(8):337-344.
  • 7VlachosA, BallS, DahlN, et al.Diagnosing and treating Diamond Blackfan anaemia:results of an international clinical consensus confe-rence[J].Br J Haematol, 2008, 142(6):859-876.
  • 8ChenS, WarszawskiJ, Bader-MeunierB, et al.Diamond-Blackfan anemia and growth status:the French registry[J].J Pediatr, 2005, 147(5):669-673.
  • 9HorosR, von LindernM.Molecular mechanisms of pathology and treatment in Diamond Blackfan anaemia[J].Br J Haematol, 2012, 159(5):514-527.
  • 10Kamimae-LanningAN, KurreP.L-leucine alleviates Diamond-Blackfan anemia[J].Blood, 2012, 120(11):2157-2158.

同被引文献15

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部